XERS News and Press, Xeris Pharmaceuticals Inc. From 06/06/19

Gainers:  La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$1.07 misses by $0.26 . Revenue of $0.25M (-3.8% Y/Y) beats by $0.18M . Press Release More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS ™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in EIH Advancing diazepam to Phase 2 based on recently reported favorable Phase 1 results ...

Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...

Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris’ diazepam Phase 2 study to be initiated in 2H2019 CHICAGO, May 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company lever...

CHICAGO, April 26, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on April 24, 2019, ...

"Freedom began on the day the first sheep wandered away from the herd ." - Marty Rubin Today, we look at a small healthcare concern with a familiar business model. The company recently addressed its funding needs, has a potential product approval on the horizon, and is selling near all-ti...

CHICAGO, March 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on March 27, 2019, ...

Xeris Pharmaceuticals ( XERS +0.8% ) is up on light volume on the heels of new data on its ready-to-use (RTU) room-temperature liquid glucagon. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented at AMCP reinforce the utility of Xeris’ ready-to-use, liquid-stable glucagon Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leve...